397 related articles for article (PubMed ID: 25785934)
1. Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe.
Poluzzi E; Raschi E; Godman B; Koci A; Moretti U; Kalaba M; Wettermark B; Sturkenboom M; De Ponti F
PLoS One; 2015; 10(3):e0119551. PubMed ID: 25785934
[TBL] [Abstract][Full Text] [Related]
2. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
3. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F
Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects.
Hey JA; del Prado M; Sherwood J; Kreutner W; Egan RW
Arzneimittelforschung; 1996 Feb; 46(2):153-8. PubMed ID: 8720304
[TBL] [Abstract][Full Text] [Related]
5. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.
Raschi E; Poluzzi E; Godman B; Koci A; Moretti U; Kalaba M; Bennie M; Barbui C; Wettermark B; Sturkenboom M; De Ponti F
PLoS One; 2013; 8(11):e81208. PubMed ID: 24278396
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic overview of oral second-generation H1 antihistamines.
González MA; Estes KS
Int J Clin Pharmacol Ther; 1998 May; 36(5):292-300. PubMed ID: 9629995
[TBL] [Abstract][Full Text] [Related]
7. Second-generation antihistamines: the risk of ventricular arrhythmias.
DuBuske LM
Clin Ther; 1999 Feb; 21(2):281-95. PubMed ID: 10211532
[TBL] [Abstract][Full Text] [Related]
8. Safety of antihistamines in children.
Ten Eick AP; Blumer JL; Reed MD
Drug Saf; 2001; 24(2):119-47. PubMed ID: 11235817
[TBL] [Abstract][Full Text] [Related]
9. Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?
Cavero I; Mestre M; Guillon JM; Heuillet E; Roach AG
Drug Saf; 1999; 21 Suppl 1():19-31; discussion 81-7. PubMed ID: 10597865
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase.
Motola D; Donati M; Biagi C; Calamelli E; Cipriani F; Melis M; Monaco L; Vaccheri A; Ricci G
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1164-1171. PubMed ID: 28653802
[TBL] [Abstract][Full Text] [Related]
11. Cardiac safety of second-generation H
Cataldi M; Maurer M; Taglialatela M; Church MK
Clin Exp Allergy; 2019 Dec; 49(12):1615-1623. PubMed ID: 31519068
[TBL] [Abstract][Full Text] [Related]
12. Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs.
Hey JA; Del Prado M; Cuss FM; Egan RW; Sherwood J; Lin CC; Kreutner W
Clin Exp Allergy; 1995 Oct; 25(10):974-84. PubMed ID: 8556569
[TBL] [Abstract][Full Text] [Related]
13.
Carnovale C; Battini V; Gringeri M; Volonté M; Uboldi MC; Chiarenza A; Passalacqua G
World Allergy Organ J; 2022 Jul; 15(7):100658. PubMed ID: 35833202
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular safety of second-generation antihistamines.
Barbey JT; Anderson M; Ciprandi G; Frew AJ; Morad M; Priori SG; Ongini E; Affrime MB
Am J Rhinol; 1999; 13(3):235-43. PubMed ID: 10392245
[TBL] [Abstract][Full Text] [Related]
15. Potential cardiac toxicity of H1-antihistamines.
Yap YG; Camm AJ
Clin Allergy Immunol; 2002; 17():389-419. PubMed ID: 12113224
[TBL] [Abstract][Full Text] [Related]
16. Cardiac actions of antihistamines.
Woosley RL
Annu Rev Pharmacol Toxicol; 1996; 36():233-52. PubMed ID: 8725389
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular toxicity of antihistamines.
Smith SJ
Otolaryngol Head Neck Surg; 1994 Sep; 111(3 Pt 2):348-54. PubMed ID: 7916150
[TBL] [Abstract][Full Text] [Related]
18. Cetirizine and loratadine: minimal risk of QT prolongation.
Prescrire Int; 2010 Feb; 19(105):26-8. PubMed ID: 20455340
[TBL] [Abstract][Full Text] [Related]
19. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs.
de Abajo FJ; Rodríguez LA
Br J Clin Pharmacol; 1999 Mar; 47(3):307-13. PubMed ID: 10215756
[TBL] [Abstract][Full Text] [Related]
20. [The effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levocetirizine, loratadine treatment on the histamine-induced skin reaction and skin blood flow--a randomized, double-blind, placebo controlled trial].
Kłos K; Kruszewski J; Kruszewski R; Sułek K
Pol Merkur Lekarski; 2006 Nov; 21(125):449-53. PubMed ID: 17345838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
